文献速递冠心病

生理学指导完全血运重建在老年心肌梗死患者中的三年结局:随机临床试验

Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

FIRE试验在34个中心纳入1445例75岁及以上心肌梗死合并多支血管病变患者,随机比较生理学指导完全血运重建与仅罪犯病变治疗。

要点

  • 老年心梗多支病变患者完全血运重建3年获益持续。
  • 主要复合终点风险显著降低(HR 0.72,95%CI 0.58-0.88)。
  • 心血管死亡或心梗及心衰住院风险亦显著降低。

核心结论

  • 在75岁及以上心肌梗死合并多支血管病变患者中,生理学指导完全血运重建较仅罪犯病变治疗的获益在3年时持续存在。

研究设计与样本

  • FIRE为研究者发起的多中心前瞻性优效性随机临床试验,2019年7月18日至2021年10月25日在3国34个中心开展。
  • 共纳入1445例心肌梗死(ST段抬高或非ST段抬高)合并多支血管病变且罪犯病变成功治疗后的患者,中位年龄80(77-84)岁,男性917例(63.5%),女性528例(36.5%)。

临床怎么用

  • 对75岁及以上心肌梗死合并多支血管病变且罪犯病变已成功治疗的患者,可考虑生理学指导的完全血运重建以持续降低3年不良事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been shown to reduce cardiovascular death and MI at 1 year. However, the durability of this benefit over longer follow-up periods has been questioned by recent studies. OBJECTIVE: To determine whether the benefit of physiology-guided complete treatment, compared with culprit-only treatment, is sustained at 3 years in older patients with MI and multivessel disease. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE), was an investigator-initiated, multicenter, prospective, superiority trial conducted at 34 centers across 3 countries from July 18, 2019, to October 25, 2021. Participants were patients with MI (either ST segment or non-ST segment elevated) and multivessel disease who were hospitalized after successful treatment of the culprit lesion. Major exclusion criteria included a nonculprit lesion in the left main coronary artery and unclear identification of the culprit lesion. Data analysis was performed from March to May 2025. INTERVENTIONS: Culprit-only treatment or physiology-guided complete revascularization of nonculprit lesions. MAIN OUTCOMES AND MEASURES: The primary outcome was a patient-oriented composite end point of death, MI, stroke, or ischemia-driven revascularization. Secondary end points included a composite of cardiovascular death or MI and rate of heart failure hospitalizations. RESULTS: Among 1445 patients enrolled in the trial, the median (IQR) age was 80 (77-84) years; 917 patients were male (63.5%) and 528 female (36.5%). At 3 years, the primary outcome occurred in 165 patients (22.9%) in the physiology-guided complete revascularization group and 216 patients (29.8%) in the culprit-only group (hazard ratio [HR], 0.72; 95% CI, 0.58-0.88; P = .002). The key secondary outcome of cardiovascular death or MI occurred in a significantly lower number of patients in the physiology-guided complete revascularization group (92 patients [12.8%]) compared with the culprit-only group (132 patients [18.2%]; HR, 0.66; 95% CI, 0.50-0.88; P = .004). Hospitalizations for heart failure were more frequent in the culprit-only group compared with the physiology-guided complete group (143 [19.7%] vs 103 [14.3%]; HR, 0.73; 95% CI, 0.54-0.97; P = .03). CONCLUSIONS AND RELEVANCE: In patients 75 years or older with MI and multivessel disease, the benefit of physiology-guided complete revascularization over culprit-lesion-only treatment was sustained at 3 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03772743.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Biscaglia, Erriquez, Guiducci, et al. Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40879426. doi:10.1001/jamacardio.2025.3099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。